Boston Scientific Corporation acquired Augmenix Inc., a privately held developer of a novel therapy to reduce side effects from radiation aimed at the prostate. Our firm represented Boston Scientific in the transaction. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.
Read Boston Scientific's press release for more information on the deal.
